Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

Study Evaluating Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients

Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD

Inclusion Criteria:

• Adult male or female patients aged ≥40 years with stable moderate-to-severe COPD according to the GOLD Guidelines classification (grades II and III): forced expiratory volume in 1 second (measured between 10 to 15 minutes post-inhalation of 400 μg of salbutamol) is 30%≤FEV1<80% of the predicted normal value
• Patients naïve to both study inhaler devices, Genuair® and Breezhaler®, for at least 2 years
• Agreement to participate and voluntarily sign the informed consent form

Exclusion Criteria:

• Patients with other clinically significant uncontrolled chronic diseases, particularly body malformations or diseases affecting coordination and/or motor system
• Patients unable to read product package instructions and answer patient reported questionnaires (PASAPQ)
• Patients with any other serious or uncontrolled mental health problems
• Patients currently participating in other randomised clinical studies
• Patients with COPD exacerbation within 6 weeks before Visit 1 and patient hospitalised for COPD exacerbation within 3 months prior to Visit 1
• Patients with any other conditions that, in the investigator's opinion, might indicate the patient to be inappropriate for the study
• Patient likely to be uncooperative